Lupin launches Ipratropium Bromide nasal spray in US

Lupin Ltd has introduced Ipratropium Bromide nasal spray in the US, available in 0.03% and 0.06% strengths. These sprays, bioequivalent to Boehringer Ingelheim's Atrovent, target rhinorrhea associated with allergies, nonallergic rhinitis, and the common cold. The annual sales for Ipratropium Bromide nasal solution (Atrovent) in the US were approximately USD 63 million, according to IQVIA MAT May 2025 data.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PCLqjzw
via IFTTT